Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OM
OM logo

OM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.620
Open
3.480
VWAP
3.50
Vol
175.32K
Mkt Cap
65.19M
Low
3.330
Amount
614.20K
EV/EBITDA(TTM)
--
Total Shares
18.31M
EV
-7.52M
EV/OCF(TTM)
--
P/S(TTM)
0.45
Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
Show More

Events Timeline

(ET)
2026-02-11
16:10:00
Outset Medical Reports Q4 Revenue of $28.87M
select
2026-02-11
16:10:00
Outset Provides 2026 Revenue Guidance of $125M to $130M
select
2026-01-27 (ET)
2026-01-27
09:10:00
Outset Medical Receives FDA 510(k) Clearance
select
2026-01-12 (ET)
2026-01-12
08:50:00
Outset Medical Outlook for Continued Growth in 2026
select
2026-01-12
08:50:00
Outset Medical Appoints Karen Prange to Board of Directors
select
2026-01-05 (ET)
2026-01-05
16:10:00
Osisko Metals Appoints Jeff Hussey as COO
select

News

Yahoo Finance
9.5
02-20Yahoo Finance
Outset Medical Q4 Results Show Strong Analyst Support
  • Performance Overview: Outset Medical reported Q4 revenue of $28.90 million, a 2% year-over-year decline, while total revenue for 2025 rose 5% to $119.50 million, indicating efforts in stabilizing the sales force and expanding the deal pipeline.
  • Analyst Ratings: Despite TD Cowen and BTIG lowering their price targets to $12 and $15 respectively, both maintained 'Buy' ratings, reflecting analysts' confidence in the company's future performance, particularly with an upcoming product launch and improving margins.
  • Financial Health: By the end of 2025, Outset Medical had cash reserves of $173 million, and adjusted net loss decreased from $19.30 million to $15.10 million, indicating progress in cost control and financial stability.
  • Future Outlook: Management projected 2026 revenue between $125 million and $130 million, with a non-GAAP gross margin in the low-to-mid-40% range, demonstrating confidence in future growth and responsiveness to market demand.
seekingalpha
9.5
02-12seekingalpha
Outset Medical Reports Q4 2025 Earnings Highlights
  • Financial Performance Boost: Outset Medical reported total revenue of $119.5 million for 2025, a 5% increase over 2024, with Q4 revenue at $28.9 million and product revenue at $19.9 million, indicating robust growth in the market.
  • Margin Improvement: The non-GAAP gross margin reached 42.9% in Q4, expanding over 500 basis points year-over-year, with product gross margin exceeding 50% for the first time, showcasing significant progress in cost control and pricing strategies.
  • High Customer Satisfaction: The Tablo system is now utilized at approximately 1,000 acute care sites in the U.S., with customer satisfaction remaining above 95%, reflecting the company's ongoing commitment to customer service and product quality.
  • Optimistic Future Outlook: The company anticipates 2026 revenue between $125 million and $130 million, representing a growth rate of 5% to 9%, while gross margins are expected to remain in the low to mid-40% range, demonstrating confidence in future growth.
seekingalpha
9.5
02-11seekingalpha
Outset Medical Reports Q4 Earnings Miss
  • Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
  • Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
  • Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
  • Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
seekingalpha
9.5
02-10seekingalpha
Outset Medical to Announce Q4 Earnings on February 11
  • Earnings Announcement Schedule: Outset Medical (OM) is set to release its Q4 2023 earnings on February 11 after market close, with a consensus EPS estimate of -$0.68, reflecting an 83.8% year-over-year decline, indicating significant profitability challenges for the company.
  • Revenue Expectations Decline: Analysts project quarterly revenue of $28.9 million, down 2.0% year-over-year, suggesting that the company may face competitive pressures that could hinder its future growth potential.
  • Historical Performance Review: Over the past two years, OM has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, indicating some capacity to exceed expectations, although recent downward revisions may impact investor confidence.
  • Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have had no upward revisions and one downward revision, reflecting a cautious market outlook on OM's future performance.
Newsfilter
5.0
01-27Newsfilter
Outset Medical Secures FDA 510(k) Clearance for Next-Gen Tablo Platform
  • FDA Clearance Milestone: Outset Medical's next-generation Tablo platform has received FDA 510(k) clearance, becoming the first hemodialysis system to comply with the latest 2025 cybersecurity guidelines, underscoring the company's leadership in medical technology innovation.
  • Cybersecurity Enhancements: The new platform incorporates enterprise-grade cybersecurity at the hardware, software, and cloud levels, designed to meet modern hospital IT standards, thereby enhancing security and reliability for dialysis providers in hospitals and homes.
  • Performance Improvements: With modernization of the operating system, hardware upgrades, and software enhancements, the Tablo platform's system performance is significantly improved, expected to extend the time between planned maintenance in high-acuity environments, thus increasing healthcare service efficiency.
  • Market Launch Plans: The new platform is expected to begin shipping to customers in Q2 2026, with existing Tablo users eligible for upgrades to this new cybersecurity platform, further enhancing their clinical and financial outcomes.
Globenewswire
9.5
2025-12-30Globenewswire
Outset Medical Reports Q3 Earnings Miss, Stock Plummets 48.47%
  • Earnings Miss: Outset Medical reported a non-GAAP loss of -$0.69 per share for Q3 2025, missing consensus estimates by $0.03, indicating significant pressure on profitability that could undermine investor confidence.
  • Revenue Decline: The company generated $29.43 million in revenue for the quarter, falling short of estimates by $1.27 million, reflecting weak sales growth that may complicate future financing efforts.
  • Outlook Revision: Outset Medical revised its 2025 revenue guidance to a range of $115 million to $120 million, down from $122 million to $126 million, signaling delays in closing several large opportunities that could impact long-term strategic planning.
  • Stock Plunge: Following the earnings report, Outset Medical's stock price fell by $5.85, or 48.47%, closing at $6.22, highlighting strong market concerns regarding the company's future performance.
Wall Street analysts forecast OM stock price to rise
4 Analyst Rating
Wall Street analysts forecast OM stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
7.00
Averages
11.75
High
17.00
Current: 0.000
sliders
Low
7.00
Averages
11.75
High
17.00
BTIG
Marie Thibault
Buy
downgrade
$17 -> $15
AI Analysis
2026-02-12
Reason
BTIG
Marie Thibault
Price Target
$17 -> $15
AI Analysis
2026-02-12
downgrade
Buy
Reason
BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $15 from $17 and keeps a Buy rating on the shares. With stability in the company's salesforce, a new product on the way, a broad and growing deal pipeline, strong recurring revenue, and improving margins, this was a solid quarter for rebuilding credibility, the analyst tells investors in a research note.
TD Cowen
Buy
downgrade
$15 -> $12
2026-02-12
Reason
TD Cowen
Price Target
$15 -> $12
2026-02-12
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Outset Medical to $12 from $15 and keeps a Buy rating on the shares. The firm said the company's results met expectations and set appropriate 2026 guidance expectations.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OM
Unlock Now

Valuation Metrics

The current forward P/E ratio for Outset Medical Inc (OM.O) is -1.28, compared to its 5-year average forward P/E of -7.65. For a more detailed relative valuation and DCF analysis to assess Outset Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.65
Current PE
-1.28
Overvalued PE
-1.11
Undervalued PE
-14.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.99
Current EV/EBITDA
0.21
Overvalued EV/EBITDA
-0.99
Undervalued EV/EBITDA
-12.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.11
Current PS
0.56
Overvalued PS
14.17
Undervalued PS
0.05

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

low float medical tech stock
Intellectia · 68 candidates
Market Cap: 50.00M - 5.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchRegion: USPrice: $1.00 - $50.00Beta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000Floating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
XLO logo
XLO
Xilio Therapeutics Inc
50.19M
LPCN logo
LPCN
Lipocine Inc
54.02M
LFVN logo
LFVN
LifeVantage Corp
54.88M
CLNN logo
CLNN
Clene Inc
63.49M
OM logo
OM
Outset Medical Inc
64.46M
ACET logo
ACET
Adicet Bio Inc
64.58M
which crypto had highest buyers today
Intellectia · 1018 candidates
Turnover 24h: >= 1
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.36T
ETH logo
ETH
Ethereum
238.14B
USD1 logo
USD1
World Liberty Financial USD
5.02B
SOL logo
SOL
Solana
48.39B
XRP logo
XRP
XRP
87.23B
BNB logo
BNB
BNB
85.23B
go below 60
Intellectia · 1018 candidates
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.32T
ETH logo
ETH
Ethereum
233.78B
XRP logo
XRP
XRP
86.49B
BNB logo
BNB
BNB
82.22B
SOL logo
SOL
Solana
46.07B
TRX logo
TRX
TRON
26.38B
cryptos under $1
Intellectia · 949 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
TRX logo
TRX
TRON
26.32B
DOGE logo
DOGE
Dogecoin
15.66B
ADA logo
ADA
Cardano
9.45B
USDE logo
USDE
USDe
6.42B
CC logo
CC
Canton Network
6.39B
USD1 logo
USD1
World Liberty Financial USD
5.37B
crypto under 1 dollar
Intellectia · 936 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
TRX logo
TRX
TRON
26.97B
DOGE logo
DOGE
Dogecoin
17.07B
ADA logo
ADA
Cardano
10.24B
CC logo
CC
Canton Network
6.61B
USDE logo
USDE
USDe
6.55B
XLM logo
XLM
Stellar
5.67B
high risk investments, or crypto
Intellectia · 483 candidates
Turnover 24h: >= 100,000Market Cap: 5.00M - 1000.00M
Ticker
Name
Market Cap$
top bottom
FIGHT logo
FIGHT
FIGHT
48.73M
SKR logo
SKR
SKR
237.08M
ELSA logo
ELSA
ELSA
37.65M
SENT logo
SENT
SENT
220.90M
YZY logo
YZY
YZY MONEY
100.82M
XRD logo
XRD
Radix
43.68M
tell me a stock ticker that is a buy now
Intellectia · 24 candidates
Analyst Consensus: Strong BuyPe Ttm: <= 20Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $15.00Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
ATGE logo
ATGE
Adtalem Global Education Inc
4.42B
ARDX logo
ARDX
Ardelyx Inc
1.94B
OCS logo
OCS
Oculis Holding AG
1.51B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
ANNX logo
ANNX
Annexon Inc
1.02B
CTMX logo
CTMX
CytomX Therapeutics Inc
896.31M

Whales Holding OM

G
GMT Capital Corp.
Holding
OM
-6.77%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Outset Medical Inc (OM) stock price today?

The current price of OM is 3.56 USD — it has increased 1.14

What is Outset Medical Inc (OM)'s business?

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

What is the price predicton of OM Stock?

Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is11.75 USD with a low forecast of 7.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Outset Medical Inc (OM)'s revenue for the last quarter?

Outset Medical Inc revenue for the last quarter amounts to 28.87M USD, decreased -2.01

What is Outset Medical Inc (OM)'s earnings per share (EPS) for the last quarter?

Outset Medical Inc. EPS for the last quarter amounts to -1.07 USD, decreased -85.32

How many employees does Outset Medical Inc (OM). have?

Outset Medical Inc (OM) has 310 emplpoyees as of March 30 2026.

What is Outset Medical Inc (OM) market cap?

Today OM has the market capitalization of 65.19M USD.